Ricardo Alonso-Zaldivar, reporter, Washington, D.C., for using cost figures obtained exclusively from Medicare actuaries to describe how the program’s safeguard for consumers with high drug costs had turned into a way for pharmaceutical companies to collect billions of taxpayer dollars for their most pricey products. Analysts worry the development could threaten the future of the Medicare drug program.
Pricey drugs overwhelm Medicare safeguard
